Hudson Bay Capital Management LP Immatics N.V. Transaction History

Hudson Bay Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$10.23 - $12.94 $2.56 Million - $3.24 Million	-250,557 Reduced 52.68%	225,023 $2.36 Million
Q4 2023 Feb 14, 2024	BUY	$7.36 - $10.89 $552,000 - $816,750	75,000 Added 18.72%	475,580 $5.01 Million
Q3 2023 Nov 14, 2023	BUY	$11.01 - $12.62 $330,300 - $378,600	30,000 Added 8.1%	400,580 $4.64 Million
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $921,033 - $1.98 Million	155,580 Added 72.36%	370,580 $4.28 Million
Q1 2023 May 16, 2023	BUY	$6.74 - $9.44 $340,855 - $477,399	50,572 Added 30.76%	215,000 $1.48 Million
Q1 2023 May 15, 2023	BUY	$6.74 - $9.44 $1.11 Million - $1.55 Million	164,428 New	164,428 $1.13 Million

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $522M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.